Amneal Builds Integrated Biosimilars Platform with Kashiv Acquisition

Amneal Pharmaceuticals (Amneal) has entered into a definitive agreement to acquire US-based Kashiv BioSciences (Kashiv), a vertically integrated biopharmaceutical company, in a move that reflects the rising competition in the global biosimilars market as a wave of biologic therapies approaches loss of exclusivity over the next decade, the company announced on April 22, 2026. The transaction, which includes a mix of cash and equity consideration alongside milestone-based payments, is expected to close in the second half of 2026, pending shareholder and regulatory approvals.¹

Under the agreement, Amneal will acquire 100% of Kashiv for $375 million of cash and $375 million of equity payable at closing. In addition, the company may pay Kashiv up to $350 million in potential payments contingent upon reaching certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing.

The proposed acquisition comes at a time when more than $300 billion in biologic medicines are projected to lose exclusivity over the next decade. This anticipated shift is widely viewed as a key inflection point for biosimilar adoption, with implications for pricing dynamics, patient access, and healthcare system costs globally, according to Amneal.¹

How does the Kashiv acquisition position Amneal in the biosimilars market?

Kashiv brings established capabilities in biosimilar development and manufacturing, including a pipeline of clinical and commercial-stage assets. By integrating these capabilities with Amneal’s commercial infrastructure, the combined entity aims to establish a fully integrated biosimilars platform that encompasses research, development, manufacturing, and commercialization.

The companies indicated that the combined platform could enable multiple biosimilar launches annually. They expect to launch more than 12 commercial biosimilars by 2030 and to have more than 20 additional candidates in development.

“As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market,” said Chirag Patel, co-founder and co-chief executive officer, Amneal, in a company press release.¹ “With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of US affordable medicines.”

What could this deal signal about biosimilar market evolution?

The transaction highlights broader industry trends toward consolidation and platform-building in the biosimilars sector. As development costs remain high and regulatory requirements complex, companies are increasingly seeking scale and operational efficiency to remain competitive.²

“By combining Kashiv’s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward,” said Chintu Patel, co-founder and co-chief executive officer, Amneal, in the release.¹

From an industry perspective, such consolidation may support broader biosimilar uptake by improving supply reliability and expanding product portfolios. However, the degree to which this translates into sustained pricing competition and improved access may vary across markets and therapeutic categories.³

How might this deal impact future biosimilar development and access?

Kashiv’s existing infrastructure, which includes integrated R&D, clinical, manufacturing, and regulatory capabilities, may enhance Amneal’s ability to advance biosimilar candidates through development and approval pathways more efficiently. The companies also highlighted potential financial and operational synergies, including the elimination of certain milestone and royalty obligations and improved cost structures over time.

“We are thrilled to combine Kashiv’s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the US,” said Sandeep Athalye, CEO, Kashiv BioSciences, in the release.1 “Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.”

The deal may also highlight how companies are preparing for the next phase of biosimilar competition. As biologics representing significant market value approach patent expiry, the ability to rapidly develop, manufacture, and commercialize biosimilars at scale could shape competitive dynamics and influence long-term access to biologic therapies. However, the ultimate impact will depend on regulatory outcomes, market adoption, and execution following the transaction’s completion.⁴

References

1. Amneal Pharmaceuticals. Amneal agrees to acquire kashiv biosciences to create global biosimilar leader; reports strong preliminary first quarter 2026 financial results and raises FY2026 standalone guidance. Published April 22, 2026. Accessed April 22, 2026. https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Agrees-to-Acquire-Kashiv-BioSciences-to-Create-Global-Biosimilar-Leader-Reports-Strong-Preliminary-First-Quarter-2026-Financial-Results-and-Raises-FY2026-Standalone-Guidance/default.aspx
2. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469-478. https://pmc.ncbi.nlm.nih.gov/articles/PMC4031732/
3. Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. The price effects of biosimilars in the United States. Value in Health 2025;28(5):742-750. doi: 10.1016/j.jval.2025.02.008
4. Tu SS, Goode R, Turner M, Van de Wiele V. Accelerating biosimilar market access: the case for allowing earlier standing. Journal of Law and the Biosciences 2025;12(1):lsae030. doi: 10.1093/jlb/lsae030